


## Innovation in Unique TandAb Antibody Therapeutics

### Affimed is an Antibody Platform and Product Company

Affimed develops unique antibody therapeutics as novel and better treatments for oncological indications such as Non-Hodgkin lymphoma, Hodgkin lymphoma, and solid tumors, as well as for inflammatory diseases. We have generated a comprehensive pipeline of antibody product candidates based on our proprietary TandAb technology platform.





TandAbs comprise only human antibody variable domains and have four binding sites for two targets.

TandAbs possess excellent binding properties and product stability. They promise increased therapeutic potential and superior safety profiles compared to monoclonal antibodies. Furthermore, when compared to antibody fragments and scaffolds, TandAbs have a much longer half-life. Robust GMP production and downstream processes have been established with renowned partners.

### Affimed's product pipeline

Compound (Target)	Indications	Discovery	Pre-Clinical	Phase I	Phase II
<b>AFM13</b> (CD30 x CD16)	Hodgkin's Lymphoma	[Progress bar: Discovery to Phase II]			
<b>AFM11</b> (CD19 x CD3)	Non-Hodgkin's Lymphoma	[Progress bar: Discovery to Phase II]			
<b>AFM12</b> (CD19 x CD16)	Non-Hodgkin's Lymphoma	[Progress bar: Discovery to Phase I]			
<b>AFM15</b> (CD3)	Autoimmune Diseases	[Progress bar: Discovery to Phase I]			
<b>AFM19</b> (Chemokine)	Asthma, COPD	[Progress bar: Discovery to Phase I]			
<b>AFM20</b> (EpCAM)	Solid Tumors	[Progress bar: Discovery to Phase I]			
<b>AFM21</b> (EGFR)	Solid Tumors	[Progress bar: Discovery to Phase I]			

2010  2012 (planned) 

### ***Lymphoma Lead Programs***

AFM 13 for the treatment of Hodgkin's lymphoma has completed preclinical development and will enter clinical studies in mid 2010. Orphan Drug Designation has been granted in 2009 for both the US and Europe.

AFM 11 and AFM 12 for Non-Hodgkin's lymphoma are currently in late stage preclinical development and are expected to enter clinical studies in 2011.

### ***Business Strategy***

**Affimed is building a mature pipeline of unique therapeutic antibodies for partnership following preclinical or clinical proof of concept**

Based on its proprietary TandAb technology platform, Affimed has generated a portfolio of innovative therapeutic TandAbs targeting attractive indications with high medical need. Our product candidates were selected against targets for which products are on the market or in advanced clinical development such as CD19, CD30, CD3, EpCAM, EGFR and others.

TandAb molecules have the potential to become the "next generation" therapeutic antibodies. Based on the mode of action, Affimed's products act as a RECRUIT-TandAb via recruitment of immune effector cells, e.g. T-cells or NK-cells, or as "BiBLOCK" TandAb via dual inhibition of two targets, e.g. growth factors in the signalling pathway.

Affimed plans to establish partnerships based on its proprietary TandAb platform and its product portfolio. We have access to fully human antibody libraries and have successfully generated more than 20 TandAb antibody candidates. We are currently evaluating partnerships for the construction and development of RECRUIT or BiBLOCK TandAbs either derived from existing antibodies or by *de novo* generation of fully human antibody fragments against targets provided from the partner.

### ***Company Background***

Affimed was founded in 2000 in Heidelberg as a spin-off from the German Cancer Research Centre (DKFZ), Heidelberg, and employs 26 people. We are backed by a peer group of investors including Orbimed, Aeris, LSP, BioMed Invest and Novo Nordisk A/S.

### ***Business Development Contact***

Dr. Erich Rajkovic    Email: [E.Rajkovic@affimed.com](mailto:E.Rajkovic@affimed.com)    Tel.: +49 6221 65307 66